Publications

A Phase II Trial of an Extended-Release siRNA Implant Targeting KRASG12D/V in Locally Advanced Pancreatic Cancer

Alagesan B, Varghese AM, Ang C, Gutierrez M, Kamar M, Passhak M, Geva R, Yarom N, et al.

Clin Cancer Res

Anatomical dynamics define cancer cachexia subtypes and identify systemic inflammation as a marker of lethal wasting

Boscenco S, Castillon VJ, Wang J, Tse E, Freeman SS, Bakouny Z, Mohan S, Guo XA, et al.

medRxiv

ASO Visual Abstract: Outcomes of First-versus Second-Line Hepatic Artery Infusion Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma

Nasar N, Armstrong M, Chou JF, Gonen M, Soares KC, Balachandran VP, Drebin JA, Kingham TP, et al.

Ann Surg Oncol

Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer

Wolpin BM, Park W, Garrido-Laguna I, Spira A, Starodub A, Sommerhalder D, Punekar SR, et al., for the RMC-6236-001 Investigators

N Engl J Med

Deep Learning Enabled 3D Multi-Omic Analysis Reveals Molecular Signatures of Heterogeneous Response to Chemotherapy in Pancreatic Cancer

Forjaz A, Mojdeganlou H, Valentin A, Wetzel M, Lvovs D, Deshpande A, Shin SM, Piya S, et al.

bioRxiv

Dual pancreatic carcinomas: clonally related or independent primaries?

Schoenfeld JD, Ravichandran V, Tarcan Z, Sahin-Ozkan H, Richards AL, Bilani N, Chou JF, O'Connor CA, et al.

NPJ Precis Oncol

Genomic evolution of pancreatic cancer at single-cell resolution

Zhang H, Sashittal P, Karnoub ER, Jakatdar A, Umeda S, Hong J, Noronha AM, Cardenas A 3rd, et al.

Nat Genet

IL10R Inhibition Induces Neutrophil Tumoricidal Activity

Khalil DN, Gomez R, Regev A, Samaan F, Marouf Y, Budhu S, Hirschhorn D, Schulze I, et al.

Cancer Immunol Res

Maximal Ablative Irradiation Because of Encasement for Patients With Locally Advanced Pancreatic Cancer: A Nonrandomized Clinical Trial

Reyngold M, Wei AC, O'Reilly EM, D'Angelica MI, Kingham TP, Soares KC, Varghese AM, White C, et al.

JAMA Surg

Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer

Cowzer D, Walch H, Atri P, Shah F, Huq R, Thummalapalli R, Nagib F, Varghese A, et al.

Clin Cancer Res

Molecular determinants of outcome to gemcitabine, cisplatin, and nab-paclitaxel in patients with advanced biliary tract cancer

Kim D, Sim NS, Woo S, Kim MH, Lee CK, Hong SS, Kim SH, Hwang HK, Kang CM, Lee WJ, Jo JH, Chung T, Hwang S, Kang B, Kim JS, Kwon CI, Kim S, Chon HJ, Kim CG, Park YN, Choi HJ

Clinical and Molecular Hepatology 32(2), 721–736

Myofibroblasts Induce Neuroplasticity to Promote Pancreatic Inflammation and Cancer Progression

Nigri J, Lan W, Fung ML, Kayser C, Deschênes A, Hinds J, Kaushalya S, Pawlak SA, et al.

Cancer Discov

Outcomes of First Versus Second-Line Hepatic Artery Infusion Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma

Nasar N, Armstrong M, Chou JF, Gonen M, Soares KC, Balachandran VP, Drebin JA, Kingham TP, et al.

Ann Surg Oncol

Pancreatic Cancer: Translating Tumor Biology into Actionability

Balogun FO, Sherman MH, Park W, Soares KC, Reyngold M, Schoenfeld JD, Singhal A, Iacobuzio-Donahue CA, et al.

Cancer Discov

Pembrolizumab and Olaparib in HRD Metastatic Pancreatic Cancer: The POLAR Trial

Park W (Corresponding Author), O’Reilly E, et al.

Nature Medicine

POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer

Park W, Umeda S, Hilmi M, O'Connor C, Sharma R, Tezcan N, Zhang H, Zhu Y, et al.

bioRxiv

Precision Medicine in Pancreatic Cancer: Targeting KRAS and Beyond

Schürmann H, Park W, O'Kane GM, Sciortino C, Niger M, Reichert M, Olive KP, Pretzell I, et al.

Target Oncol

Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer

Park W, Kasi A, Spira AI, Paz-Ares Rodríguez L, Herzberg BO, Pelster MS, et al.

N Engl J Med

Transcriptomic Plasticity Is a Hallmark of Metastatic Pancreatic Cancer

Jiménez-Sánchez A, Persad S, Hayashi A, Umeda S, Sharma R, Xie Y, Mehta A, Park W, et al.

Cancer Res

Treating Pancreatic Ductal Adenocarcinoma: The Targeted Revolution is Here

May MS, Park W, O'Reilly EM

Drugs

Understanding the symptoms and impacts of living with metastatic pancreatic adenocarcinoma: a prospective, noninterventional qualitative study

Oh M, Chang L, Matney C, Fuldeore R, Perez E, Alici Y, Buzaglo J, Mao M, et al.

Oncologist

Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohort

Keane F, O'Connor C, Moss D, Chou JF, Perry MA, Crowley F, Saxena P, Chan A, et al.

J Natl Cancer Inst

Clinical Utility and Prognostic Implications of Circulating Cell-Free DNA in Biliary Tract Cancer

Cowzer D, Darmofal M, Seier K, Thummalapalli R, Walch H, El Dika I, Khalil DN, Park W, et al.

JCO Precis Oncol

Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma

Keane F, Saadat LV, O'Connor CA, Chou JF, Bowman AS, Xu F, Crowley F, Debnath N, et al.

J Natl Cancer Inst

Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival

Varghese AM, Perry MA, Chou JF, Nandakumar S, Muldoon D, Erakky A, … Park W, …

Nature Medicine 31(2), 466–477

Influence of biologic sex and obesity on liver recurrence and survival in patients undergoing upfront surgery for pancreatic adenocarcinoma

Judge SJ, Manin E, Chou J, Torphy RJ, McIntyre CA, Balachandran VP, D'Angelica MI, Drebin JA, et al.

Cancer

Intrahepatic Cholangiocarcinoma: Recurrence Patterns, Genomics, and Survival

Chandra P, Song Y, Drill E, Wei AC, Kemeny N, Cercek A, Connell L, Harding J, et al.

JCO Precis Oncol

Nonoperative Management of Technically Resectable Pancreatic Cancer With Ablative Radiation Therapy

Reyngold M, Schoenfeld JD, O'Reilly EM, Varghese AM, White C, Zinovoy M, Romesser PB, Wu AJ, et al.

JAMA Oncol

Pembrolizumab and Olaparib (POLAR) Maintenance Therapy in Metastatic Pancreatic Cancer With or Without Homologous Repair Deficiency: A Biomarker Selected Phase II Trial

Park W, O'Connor C, Chou J, Hilmi M, Tarcan Z, Schwartz C, Larsen M, Chatila W, et al.

Res Sq

RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer

Sethna Z, Guasp P, Reiche C, Milighetti M, Ceglia N, Patterson E, Lihm J, …

Nature 639(8056), 1042–1051

Survival Outcomes and Genetic Characteristics of Resected Pancreatic Acinar Cell Carcinoma

Blair AB, Radomski SN, Chou J, Liu M, Howell TC, Park W, O'Reilly EM, Zheng L, et al.

Ann Surg Oncol

The Noncoding Mutational Landscape of Pancreatic Cancer Reveals Recurrent Somatic Mutations in Enhancer Regions

Hayashi A, Ho YJ, Makohon-Moore AP, Zucker A, Hong J, Umeda S, Karnoub ER, Huang J, et al.

Cancer Res Commun

Automated real-world data integration improves cancer outcome prediction

Jee J, Fong C, Pichotta K, Tran TN, Luthra A, Waters M, Fu C, Altoe M, …

Nature 636(8043), 728–736

Concordance in Oncogenic Alterations Between the Primary Tumor and Advanced Disease: Insights Into the Heterogeneity of Intrahepatic Cholangiocarcinoma

McIntyre SM, Preston WA, Walch H, Sharib J, Kundra R, Sigel C, Lidsky ME, Allen PJ, et al.

JCO Precis Oncol

Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer

McIntyre CA, Grimont A, Park J, Meng Y, Sisso WJ, Seier K, Jang GH, … Park W, …

Cancer Cell 42(9), 1614–1629

EGFR-directed antibodies promote HER2 ADC internalization and efficacy

Gupta A, Michelini F, Shao H, Yeh C, Drago JZ, Liu D, Rosiek E, Romin Y, et al.

Cell Rep Med

Extrahepatic Cholangiocarcinoma: Genomic Variables Associated With Anatomic Location and Outcome

Preston WA, Drill E, Boerner T, Gelfer R, Harding JJ, O'Reilly EM, Cercek A, Abou-Alfa G, et al.

JCO Precis Oncol

KRAS Variants Are Associated With Survival Outcomes and Genomic Alterations in Biliary Tract Cancers

Gelfer R, Gulla A, Kalvin HL, Song Y, Harding J, Abou-Alfa GK, O'Reilly EM, Park W, et al.

JCO Precis Oncol

Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer

O'Connor CA, Harrold E, Lin D, Walch H, Gazzo A, Ranganathan M, Kane S, Keane F, et al.

JAMA Oncol

Morbidity and mortality in patients with stage IV pancreatic adenocarcinoma and acute cholangitis: Outcomes and risk prognostication

Singh I, Chou JF, Capanu M, Park J, Yu KH, Varghese AM, Park W, Zervoudakis A, et al.

Pancreatology

Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease

Keane F, Chou JF, Walch H, Schoenfeld J, Singhal A, Cowzer D, Harrold E, O'Connor CA, et al.

J Natl Cancer Inst

Salvage Ablative Radiotherapy for Isolated Local Recurrence of Pancreatic Adenocarcinoma following Definitive Surgery

Dee EC, Ng VC, O'Reilly EM, Wei AC, Lobaugh SM, Varghese AM, Zinovoy M, Romesser PB, et al.

J Clin Med

SWI/SNF Complex-Deficient Undifferentiated Carcinoma of the Pancreas: Clinicopathologic and Genomic Analysis

Yavas A, Ozcan K, Adsay NV, Balci S, Tarcan ZC, Hechtman JF, Luchini C, Scarpa A, et al.

Mod Pathol

Dramatic, durable response to therapy in gBRCA2-mutated pancreas neuroendocrine carcinoma: opportunity and challenge

Keane F, Bajwa R, Selenica P, Park W, Roehrl MH, Reis-Filho JS, Mandelker D, O'Reilly EM

NPJ Precis Oncol

Durable Response after Olaparib Treatment for Perihilar Cholangiocarcinoma with Germline BRCA2 Mutation

Costa BA, Tallón de Lara P, Park W, Keane F, Harding JJ, Khalil DN

Oncol Res Treat

Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell Carcinoma

Mandelker D, Marra A, Zheng-Lin B, Selenica P, Blanco-Heredia J, Zhu Y, Gazzo A, Wong D, et al.

J Clin Oncol

KRAS(G12D) inhibition in pancreatic cancer: Fas expression facilitates immune clearance

Yeh C, Park W, Yaeger R

Dev Cell

Pancreatic Cancer: BRCA Targeted Therapy and Beyond

Keane F, O'Connor CA, Park W, Seufferlein T, O'Reilly EM

Cancers (Basel)

Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer

Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, Lihm J, … Park W, …

Nature 618(7963), 144–150

Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden

Florou V, Floudas CS, Maoz A, Naqash AR, Norton C, Tan AC, Sokol ES, Frampton G, et al.

J Immunother Cancer

Biomarker analysis from a phase II multi-institutional study of nivolumab in patients with advanced refractory biliary tract cancer

Kim DW, Kim YC, Kovari BP, Chung V, Alese OB, El-Rayes BF, Li D, Park W, et al.

Eur J Cancer

Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer

Yu KH, Park J, Mittal A, Abou-Alfa GK, El Dika I, Epstein AS, Ilson DH, Kelsen DP, et al.

Cancer

Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice

Park W, O'Connor CA, Bandlamudi C, Forman D, Chou JF, Umeda S, Reyngold M, Varghese AM, et al.

Clin Cancer Res

Homologous Recombination Deficiency in Pancreatic Cancer: Poly (ADP-ribose) Polymerase Inhibition, Checkpoint Inhibition, or a Combination of Both?

Keane F, Park W, O'Reilly EM

JCO Precis Oncol

Methylation Analyses Reveal Promoter Hypermethylation as a Rare Cause of "Second Hit" in Germline BRCA1-Associated Pancreatic Ductal Adenocarcinoma

Zheng-Lin B, Rainone M, Varghese AM, Yu KH, Park W, Berger M, Mehine M, Chou J, et al.

Mol Diagn Ther

MITI minimum information guidelines for highly multiplexed tissue images

Schapiro D, Yapp C, Sokolov A, Reynolds SM, Chen YA, Sudar D, Xie Y, …

Nature Methods, 10.1038/s41592-022-01415-4

Stereotactic ablative radiation for pancreatic cancer on a 1.5 Telsa magnetic resonance-linac system

Tringale KR, Tyagi N, Marsha Reyngold, Romesser PB, Wu A, O'Reilly EM, Varghese AM, Godoy Scripes P, et al.

Phys Imaging Radiat Oncol

A Review of Pancreatic Cancer-Reply

Park W, Chawla A, O'Reilly EM

JAMA

Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer

Reyngold M, O'Reilly EM, Varghese AM, Fiasconaro M, Zinovoy M, … Park W, …

JAMA Oncology 7(5), 735–738

Early-onset pancreas cancer: clinical descriptors, genomics, and outcomes

Varghese AM, Singh I, Singh R, Kunte S, Chou JF, Capanu M, Wong W, … Park W, …

JNCI: Journal of the National Cancer Institute 113(9), 1194–1202

Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors

Dunbar A, Bolton KL, Devlin SM, Sanchez-Vega F, Gao J, Mones JV, … Park W, …

Blood 137(15), 2103–2113

Leptomeningeal disease in pancreas ductal adenocarcinoma: A manifestation of longevity

O'Connor CA, Park JS, Kaley T, Kezlarian B, Edelweiss M, Yang TJ, Park W, Reidy D, et al.

Pancreatology

Local Control and Survival After Induction Chemotherapy and Ablative Radiation Versus Resection for Pancreatic Ductal Adenocarcinoma With Vascular Involvement

Jolissaint JS, Reyngold M, Bassmann J, Seier KP, Gönen M, Varghese AM, Yu KH, Park W, et al.

Ann Surg

Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes

Momtaz P, O'Connor CA, Chou JF, Capanu M, Park W, Bandlamudi C, Berger MF, Kelsen DP, et al.

Cancer

Pancreatic cancer: a review

Park W, Chawla A, O'Reilly EM

JAMA 326(9), 851–862

Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics

Mezquita L, Preeshagul I, Auclin E, Saravia D, Hendriks L, Rizvi H, Park W, Nadal E, et al.

Eur J Cancer

Targeting DNA damage repair pathways in pancreas cancer

Crowley F, Park W, O'Reilly EM

Cancer Metastasis Rev

Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma

McIntyre CA, Lawrence SA, Richards AL, Chou JF, Wong W, Capanu M, … Park W, …

Cancer 126(17), 3939–3949

Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer

Park W, Mezquita L, Okabe N, Chae YK, Kwon D, Saravia D, Auclin E, Planchard D, et al.

Br J Cancer

Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort

Naqash AR, Ricciuti B, Owen DH, Florou V, Toi Y, Cherry C, Hafiz M, De Giglio A, et al.

Cancer Immunol Immunother

Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection

Park W, Chen J, Chou JF, Varghese AM, Yu KH, Wong W, Capanu M, …

Clinical Cancer Research 26(13), 3239–3247

Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort

Naqash AR, Ricciuti B, Owen DH, Florou V, Toi Y, Cherry C, Hafiz M, … Park W, …

Cancer Immunology, Immunotherapy 69(7), 1177–1187

Reply to N. Fazio

O'Reilly EM, Park W, Kelsen DP

J Clin Oncol

Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial

Wilky BA, Trucco MM, Subhawong TK, Florou V, Park W, Kwon D, …

The Lancet Oncology 20(6), 837–848

Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer

Chae YK, Viveiros P, Lopes G, Sukhadia B, Sheikh MM, Saravia D, Florou V, Sokol ES, et al.

J Thorac Oncol

Clinical implications of circulating tumor DNA tumor mutational burden (ctDNA TMB) in non-small cell lung cancer

Chae YK, Davis AA, Agte S, Pan A, Simon NI, Iams WT, Cruz MR, … Park W, …

The Oncologist 24(6), 820–828

Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, et al.

J Immunother Cancer

Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review

Singh RR, Goldberg J, Varghese AM, Yu KH, Park W, O'Reilly EM

Cancer Treat Rev

Perspectives: Neutrophil-to-lymphocyte Ratio as a Potential Biomarker in Immune Checkpoint Inhibitor for Non-Small-Cell Lung Cancer

Park W, Lopes G

Clin Lung Cancer

Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, …

Journal for Immunotherapy of Cancer 7(1), 131

Autoimmune haemolytic anaemia in a patient with advanced lung adenocarcinoma and chronic lymphocytic leukaemia receiving nivolumab and intravenous immunoglobulin

Algaze SD, Park W, Harrington TJ, Mudad R

BMJ Case Rep

Complete response to ipilimumab and nivolumab therapy in a patient with extensive extrapulmonary high-grade small cell carcinoma of the pancreas and HIV infection

Husnain M, Park W, Ramos JC, Johnson TE, Chan J, Dasari A, Mudad R, Hosein PJ

J Immunother Cancer

Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non–Small Cell Lung Cancer

Aguiar PN Jr, Haaland B, Park W, San Tan P, Del Giglio A, …

JAMA Oncology 4(8), 1080–1084

Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab

Park W, Kwon D, Saravia D, Desai A, Vargas F, El Dinali M, Warsch J, Elias R, et al.

Clin Lung Cancer

The Concept of Biosimilars: From Characterization to Evolution-A Narrative Review

Farhat F, Torres A, Park W, de Lima Lopes G, Mudad R, Ikpeazu C, Abi Aad S

Oncologist

Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer

Tiesi G, Park W, Gunder M, Rubio G, Berger M, Ardalan B, Livingstone A, Franceschi D

J Surg Res

Heat shock protein 90 promotes epithelial to mesenchymal transition, invasion, and migration in colorectal cancer

Nagaraju GP, Long TE, Park W, Landry JC, Taliaferro-Smith LT, Farris AB, …

Molecular Carcinogenesis 54(10), 1147–1158

Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3

Ganji PN, Park W, Wen J, Mahaseth H, Landry J, Farris AB, Willingham F, …

Angiogenesis 16(4), 903–917

Crosstalk from survival to necrotic death coexists in DU-145 cells by curcumin treatment

Kang D, Park W, Lee S, Kim JH, Song JJ

Cell Signal

New perspectives of curcumin in cancer prevention

Park W, Amin ARMR, Chen ZG, Shin DM

Cancer Prevention Research 6(5), 387–400

A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment

Zhang H, Yun S, Batuwangala TD, Steward M, Holmes SD, Pan L, Tighiouart M, Shin HJ, et al.

Int J Cancer